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Abstract 
Background: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been 
used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the 
patients shows noticeable clinical response.  
Patients and Methods: Sixty-seven newly diagnosed NPC patients from 2005 to 2007 and 
21 healthy donors were collected. Immunological parameters and immune function of 
PBMCs and EBV-CTL were analyzed by flow cytometer analysis (FACS) and  51Cr re-
leasing experiment; Molecular characteristics on NPC tumor cells were investigated by 
immunochemical staining and statistic analysis. 
Results: NPC patients can be classified into two groups based on the percentage of CD3+ 
T  cells  in  peripheral  blood  before  accepted  any  treatment,  (>52.6%,  mean-2SE  from 
healthy controls, NPC Group 1; <52.6%, NPC Group 2). The patients in Group 2 showed 
a  significant  decrease  of  CD3+CD8+  T-cells,  CD3+CD4+  T-cells  and  CD3+CD45RO+ 
memory T cells, and increase of CD3-CD16+ NK cells compared to Group 1 patients and 
healthy controls (P<0.001). EBV-specific T cell responses, were weaker in this group of 
patients and their tumor cells expressed lower levels of the EBV encoded latent mem-
brane protein (LMP)-1 and HLA class II protein compared with the patients of NPC 
Group 1 (P<0.05) .  
Conclusion: These findings demonstrate that NPC patients could be distinguished on the 
basis of their immune status which will affect the efficacy of EBV-CTL immunotherapy. 
Key words: NPC, EBV-specific CTL, immunotherapy, LMP1, immunophenotype 
INTRODUCTION 
EBV  is a lymphotropic  -herpes virus that can 
transform  B-lymphocytes  in  vitro  and  is  associated 
with  malignancies  of  lymphoid  and  epithelial  cell 
origin [1-4].  EBV  is  widespread  in  humans  but  the 
infection is efficiently controlled in the vast majority 
of immunocompetent individuals due to the activa-
tion of EBV-specific T cell responses that inhibit the 
growth of virus infected cells. Studies of patients suf-
fering from Infection mononucleosis, a symptomatic 
primary EBV infection that is frequently observed in 
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adolescents,  have  shown  that  non-specific  NK-like 
effector cells and virus specific MHC class I and class 
II restricted lymphocytes synergized in controlling the 
growth of EBV infected cells but EBV-specific cyto-
toxic lymphocytes (EBV-CTL) appear to constitute the 
major component of the cellular immune response in 
healthy virus carriers [5-10].  
EBV-CTL is currently recognized as an efficient 
means  to  treat  certain  types  of  EBV-associated  ma-
lignancies.  The  most  striking  effects  have  been  ob-
tained in the treatment of post-transplantation lym-
phoproliferative  disease  (PTLD)  where  adoptive 
transfer of EBV-CTL inhibits tumor progression and 
may  even  induce  regression  and  complete  cure 
[11-13]. Some success was also reported in the treat-
ment  of  Hodgkin  lymphoma  and  NPC  [14,  15]  . 
However,  it  has  been  difficult  to  obtain  consistent 
results or stable clinic efficacy in these tumor types 
[11, 12, 16, 17]. The reason for this different behavior 
in each patient is not completely clear. Although the 
capacity  to  respond  to EBV  infection appears  to  be 
overall preserved in both HD and NPC patients [2, 
11], some imbalance of antiviral responses were also 
observed  and  active  suppression  of  EBV  specific 
T-cells responses was shown to occur at the tumor site 
[18, 19] . In this study we have looked for immuno-
logical parameters that may help to predict the effi-
cacy  of  EBV-CTL  adoptive  immunotherapy.  By  im-
munophenotyping of circulating lymphocytes from a 
series of newly diagnosed patients before the initia-
tion of treatment, we have been able to distinguish 
two groups of NPCs that behave differently with re-
gard to their response to virus infected cells. We also 
found  that  these  immunological  differences  in  pe-
ripheral blood were correlated with the levels of ex-
pression of LMP1 and HLA class II antigens in the 
tumor cells. 
MATERIAL AND METHODS 
Study subjects 
Heparinized venous blood were collected from 
21  healthy  donors  and  67  untreated  primary  naso-
pharyngeal carcinoma (NPC) patients at the Cancer 
Center of Sun-Yat Sen University during 2005-2007, 
and 36 paraffin embedded tumor samples were col-
lected from these patients in the same time. The de-
tailed  clinical  and  histopathological  information  see 
Table 1.  
Table 1. Clinical characteristics of the two groups of NPC patients 
Characteristic  No. of patients  NPC Group 1  Constituent 
ratio (%) 
NPC Group 2  Constituent 
ratio (%) 
Total  67  40    27   
Age, Years           
<50  44  27  69.2  17  62.9 
≥50  22  12  30.7  10  37.0 
Gender           
Male  53  32  80  21  77.7 
female  13  8  20  6  22.2 
Diagnosis           
Histological type           
Poorly differentiated squamous carcinoma  4  2  5  2  7.4 
Undifferentiated non-keratinizing NPC  62  38  95  25  92.6 
Grade           
T1  1  0  0  1  3.7 
T2  18  9  23.1  9  33.3 
T3  28  19  48.7  9  33.3 
T4  20  12  30.7  8  29.6 
Stage           
I-II  9  4  10.3  5  18.5 
Ⅲ-IV  58  36  92.3  22  81.4 
N stage           
N0- N1  31  19  48.7  12  44.4 
N2- N4  37  21  53.8  15  55.5 
Metastasis           
M0  65  38  95  26  92.3 
M1-4  2  2  5  1  3.7 Int. J. Biol. Sci. 2011, 7 
 
 
http://www.biolsci.org 
609 
All patients and healthy donors are South Chi-
nese living in Guangdong province for 2-3 generation. 
The Ethical Committee of the Sun-Yat Sen University 
Cancer Center has approved the study and full con-
sent was obtained from all patients and healthy do-
nors.  
Cell lines and cell culture 
Peripheral  blood  mononuclear  cells  (PBMCs) 
were  isolated  from  20  ml  heparinized  blood  by  Fi-
coll/Isopaque gradient fractionation, and monocytes 
were depleted by plastic adherence. For generation of 
EBV  transformed  lymphoblastoid  cell  lines  (LCL), 
1X106 PBMCs were incubated with concentrated su-
pernatant  of  B95-8  cultures  in  the  presence  of  1 
g/mL cyclosporin A (Sigma, USA). For generation of 
EBV  specific  CTLs  cryopreserved  PBMCs  were 
thawed and aliquots of 3x106 cells were stimulated in 
24 well plates with irradiated (4000 Rads) LCL cells at 
40:1 (responder: stimulator (R:S) ratio). After 7 days, 
viable cells were re-stimulated under the same condi-
tions,  and  3  days  later,  the  cells  were  expanded  in 
complete  RPMI  1640  medium  containing  10  UI/ml 
IL-2  (R&D  Systems  Inc).  The  cultures  were 
re-stimulated weekly. For generation of PHA blasts, 
PBMCs were stimulated with 1 g/ml PHA-L (Sigma) 
for 3 days and expanded in IL-2 containing medium. 
The HLA type was determined by sequence specific 
primer  (SSP)-PCR  in  the  Guangzhou  Organ  Trans-
plant and Tissue Typing Center. 
Serum EBV antibody titers, DNA load and cytokine 
levels 
Serum samples were collected for determining of 
EBV  specific  antibodies,  EBV  DNA  load,  and  cyto-
kines levels. IgA antibody titers against the EBV virus 
capsid  antigen  (VCA)  and  early  antigen  (EA)  were 
detected  using  a  commercial  enzyme-labeling  im-
munostaining  assay  detection  kit  (Zhongshan  Bio-
technology Company, Tianjin, China) according to the 
instruction of manufacturer. EBV DNA load was de-
termined  by  real  time  quantitative  PCR  using  the 
probe  W-67T  derived from  the  BamHI-W  region  of 
the EBV genome. The procedures for real-time quan-
titative PCR and reaction set-up were carried out as 
described previously [20]. The serum cytokine were 
analyzed  using  the  human  Th1/Th2  cytokine  Cy-
tometric Bead Array Kit (BD-Bioscience/Pharmingen, 
San Diego, CA) as described before [21].  
Phenotype and tetramer analysis 
PerCP, FITC or PE-conjugated mouse monoclo-
nal antibodies (MAbs) to CD3 (Clone UCHT1), CD4 
(Clone RPA-T4), CD8 (Clone RPA-T8), CD16 (Clone 
3G8),  CD45RA  (Clone  HI100),  CD45RO  (Clone 
UCHL1)  from  BD  Pharmingen  Company  (San  Jose, 
CA,  USA)  and  FITC-conjugated  anti-human  CD4 
(Clone RPA-T4) and PE-conjugated anti-human CD25 
(BC96) from eBioscience (San Diego, CA, USA) were 
used for surface markers analysis with a FACS AriaTM  
machine and FACS Diva software (BD Biosciences). 
The frequency of T cell specific for HLA-A2 restricted 
epitopes in LMP1 and LMP2 was analyzed by staining 
with phycoerythrin (PE)–labeled tetrameric complex 
assembled with synthetic peptides origin from LMP1 
YLQQNWWTL,  YLLEMLWRL,  ALLVLYSFA  and 
LMP2  CLGGLLTMV,  FLYALALLL,  GLGTLGAAI, 
LLW  TLVVLL  (Guangzhou  Taimo  Corporation, 
Guangzhou, China). For each sample, 105 cells were 
analyzed  using  the  FACS  AriaTM  and  FACS  Diva 
software (BD Biosciences). 
CTL activity and cytokine release 
CTL cytotoxic activity was evaluated in standard 
4h  51Cr release assays, as previously described [22]. 
The targets panel included autologous LCLs and PHA 
blasts,  allogeneic  HLA  class  I  mismatched  LCLs. 
Three patterns of cytotoxicity were characterized as 
described  [19]  ,  Pattern  I:  EBV  specific  cytotoxicity, 
characterized by efficient lysis (>25% at 10:1 R:S ratio) 
of the autologous and allogenic HLA class I matched 
LCLs and no lysis of autologous PHA blast and HLA 
class I mismatched targets, Pattern II: LAK type cy-
totoxicity, characterized by equal lysis of HLA class I 
matched and mismatched LCLs, and Pattern III: no 
cytotoxicity, where the specific lysis against all targets 
was  <10%  at  10:1  R:S  ratio.  All assays  were  run  in 
triplicate and the results are presented as the mean±
SD.  IFN-  intracellular  cytokine  staining  was  per-
formed  using  the  Cytofix/Cytoperm  Plus  kit  (BD 
PharMingen).5  x105  cells  were  stimulated  with 
PMA/inomycin (0.5-1 g/ml), auto-LCL or auto-PHA 
blast at 3:1 R:S ratio in 200 l of complete RPMI 1640 
medium  in  96-well  round  tissue  culture  plate,  con-
taining GolgiPlug (BD Phar-Mingen, San Diego, CA) 
for 4 h at 37°C.  
Immunohistochemistry 
Antibodies  used  for  immunohistochemistry 
(IHC)  were:  monoclonal  antibody  Epstein-Barr  vi-
rus/LMP1 Ab-1 (Clone CS1+CS2+CS3+CS4, Lab Vi-
sion,  USA),  mouse  anti-human  IP-10  (Lot# 
099CY39RB,  AMS  Biotechnolgy  Europe  Ltd,  Abing-
don,  UK),  CXCR4  (Lot#  AVB06,  clone  44716,  R&D 
Systems  Inc.  Minneapolis,  USA),  CD54  (ICAM-1) 
(Catalog#  MAB2130,  CHEMICON  international  Inc, 
California,  USA),  SDF-1  (Lot#  0304M092RB,  R&D), 
-microglobulin (Lot# 030, DakoCytomation,  Dako 
Norden  A/S,  Denmark),  HLA-DR  (Lot#  068,  Clone Int. J. Biol. Sci. 2011, 7 
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TAL.1B5,  Dako).  Immunohistochemistry  was  done 
according to standard protocols [23].  
The expression of immune regulation regulated 
proteins in NPC lesions by IHC was scored as[24]: in 
10  high-powered  fields  at  X40  magnification:  ‘0’  
means absent expression or  positive staining < 5% 
cells, ‘1’ means positive staining 5-25%, so ‘0-1’ was 
defined as ‘low’ expression group (including absent 
and weak expression); ‘2’ means positive staining cell 
25-50%,  ‘3’ means >50% positive staining,  ‘2-3’ was 
defined as ‘high’ expression group (including mod-
erate/strong expression) in this study. 
Statistical analysis    
Statistical analysis was performed with the SSPS 
13.0 software package (SPSS Inc, Chicago, USA), us-
ing Chi-square test, t student test, or Mann-Whitney U 
test, with level of significance set at P<0.05. 
RESULTS 
Immunophenotyping of blood lymphocytes distin-
guishes two groups of NPC patients. 
Given that only a fraction of NPC patients show 
an  obvious  clinical  response  to  adoptive  immuno-
therapy  with  EBV-specific  CTL  (EBV-CTL)  [16,  25], 
we  attempted  to  determine  if  NPC  patients  can  be 
categorized based on the immunophenotype of their 
circulating  lymphocytes  and  serum  EBV  antibody 
titers. The immunophenotypes of PBMCs from NPC 
patients and healthy EBV carriers were investigated 
by immunofluorescence staining and FACS analysis 
(Fig. 1).  
 
 
 
Figure 1. Immunophenotype of PBMCs from healthy donors, the NPC Group 1 and the NPC Group 2 patients. 
Surface markers were analyzed by FACS using directly immunofluorescence labeling in PBMCs from healthy donors 
(n=20); the NPC Group 1 patients (n=40); and the NPC Group 2 patients (n=27). * P<0.01 Int. J. Biol. Sci. 2011, 7 
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Figure 2. Frequency of LMP1 and LMP2 epitope- specific T cells. The mean percentage of T cells specific for HLA A2 
restricted on LMP1 and LMP2 was detected by EBV tetramer staining and FACS analysis in PBMCs (A) and EBV-CTL 
cultures (B) from NPC Group 1 (n=6) and NPC Group 2 (n=4).* means P<0.05 
 
 
 
The percentage of CD3+ T-cells that corresponds 
to the mean -2SE of the percentage of CD3+ T-cells in 
healthy  control  (52.6%)  was  applied  to  cut  off  the 
subgroups of NPC patients in this study, we found 
that 40 out of 67 NPC patients (59.7%) had a percent-
age of CD3+ lymphocytes above this lower limit, des-
ignated here as NPC Group 1, while the remaining 
(41.3%) of the patients had lower proportion of CD3+ 
lymphocyte,  designated  as  NPC  Group  2.  In  brief, 
NPC  Group  2  patients  showed  a  significantly  de-
creased percentage of CD3+ T-cells (44.1% VS 61.8% 
and 68.1% in NPC group 1 patients and healthy con-
trols, respectively, P<0.001), CD3+CD8+ T-cells (13.8% 
VS 23.6% and 27.1%, P<0.001) and CD3+CD4+ T-cells 
(24.9%  VS  31.6%  and  33.7%,  P<0.001)  as  well  as 
CD3+CD45RO+  memory  T  lymphocytes  (19.3%  VS 
27.2% and 28.6%, P<0.001); whereas the percentage of 
CD3-CD16+  NK  cells  was  significantly  higher  com-
pared  with  Group  1  and  healthy  controls  (34%  VS 
21.2%  and  22%,  P<0.001).  The  percentage  of 
CD4+CD25+ Treg cells was similar in NPC Group 1 
and NPC Group 2 patients and in both cases signifi-
cantly higher compared to healthy controls (7.5% and 
7.0%  VS  2.8%,  P<0.001);  while  the  percentage  of 
CD3+CD45RA+ and CD4+CD25- was lower in patients 
of  two  NPC  groups  compared  to  healthy  controls 
(19.5%  and  26.9%,  38.6%  and  21.8%  VS  25.5%  and 
37.8%, respectively, P<0.001).  
Furthermore,  we  investigated  the  frequency  of 
HLA-A2  restricted  EBV  latent  membrane  antigens 
LMP1 (YLQ, YLL and ALL) and LMP2 (FLY, GLG, 
LLW and CLG) epitopic antigen-specific CTLs in the 
peripheral blood mononuclear cells (PBMCs) from the 
patients of two NPC groups by tetramer staining. The 
percentage of CD8hightetramer+ T cells including YLQ, 
YLL,  ALL  (LMP1)  and  FLY,  GLG,  LLW  and  CLG 
(LMP2) was analyzed in PBMCs or EBV-CTL cultures 
from HLA-A2 positive samples including 6 samples 
from NPC Group 1 and 4 samples from NPC Group 2 
as shown in Fig 2A and 2B. Generally the frequency of 
LMP1  and  LMP2  epitopic  antigen-specific  CTLs  in 
PBMCs  was  much  higher  in  Group  1  compared  to 
Group  2,  moreover  the  frequency  of  YLQ  (LMP1), 
FLY, GLG and CLG (LMP2) epitopic antigen-specific 
CTLs  in  PBMCs  was  significantly  higher  in  NPC 
Group  1  compared  with  NPC  Group  2  (Fig.  2A, 
P<0,05). Int. J. Biol. Sci. 2011, 7 
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The cytokines levels, EBV-antibodies and DNA 
loading are different in NPC Group1 and NPC Group 
2 
The  serum  levels  of  Th1  (IFN,  IL-2  and 
TNFand Th2 cytokines (IL-4, IL-6 and IL-10) were 
analyzed by CBA kit in 19 healthy controls, 17 NPC 
Group 1 and 10 NPC Group 2 patients (Table 2). The 
level of IFNwas significantly higher in NPC Group 1 
patients compared to NPC Group 2 patients (P<0.05) 
while the differences in other cytokines were not sta-
tistically  significant  between  two  NPC  groups,  alt-
hough  more  samples  positive  for  TNF-  and  IL-2 
were  found  in  NPC  Group  1  patients.  However, 
compared to health donors the levels of IL-6, IL-10 
and  IFN  were  significantly increased in  both  NPC 
Group 1 and NPC Group 2 patients (P<0.05); while 
the level of TNF was significantly increased in NPC 
Group 1 patients (P<0.05).  
Furthermore, NPC Group 2 patients showed a 
significantly higher serum IgA anti EA (P<0.05), and a 
slightly higher serum IgA anti VCA and serum virus 
load compared to NPC Group 1 patients (P>0.05, Fig. 
3A  and  3B).  Taken  together,  these  findings  suggest 
that the patients in NPC Group 2 were dysfunction in 
EBV specific immunity and more difficult to control 
the EBV infection. 
 
Table 2. Cytokine levels in the serum from healthy control, and NPC Group 1 and NPC Group 2 patients. 
 
Cytokine 
Healthy Control  NPC Group 1  NPC Group 2 
Positive/Total (%)  Mean  
pg/ml 
Positive/Total (%)  Mean  
pg/ml 
Positive/Total (%)  Mean 
 pg/ml 
IFN-γ  0/19 (0)  0  15/17 (88)  4.2*  4/10 (40)  1.2*/** 
TNF-α  0/19 (0)  0  7/17 (41)  0.8*  2/10 (20)  0.3 
IL-2  1/19 (5)  0.2  4/17 (24)  0.6  0/10 (0)  0 
IL-4  0/19 (0)  0  3/17 (18)  0.5  0/10 (0)  0 
IL-6  0/19 (0)  0  15/17 (88)  2.9*  6/10 (60)  2.9* 
IL-10  0/19 (0)  0  15/17 (88)  1.7*  5/10 (50)  1.3* 
*Significant difference from healthy donors (P<0.05). 
** Significant difference from NPC group 1 patients (P<0.05). 
 
 
 
 
 
Figure 3. EBV VCA and EA antibody titers and EBV DNA load in the serum from NPC Group 1 and NPC Group 2 
patients. Antibody titers (A) to EBV VCA and EA IgA; EBV DNA load (B) in NPC Group 1 and NPC Group 2 patients. 
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The difference in activation of EBV-specific CTLs in 
vitro was identified in two NPC Groups. 
To further investigate the status of EBV specific 
immune responses the two groups of patients were 
compared for their capacity to respond to stimulation 
with autologous EBV immortalized LCL according to 
previously  established  PBMCs  restimulation  proto-
cols [26]. The procedure was successful in 10 out 12 
patients in NPC Group 1, while only 6 out of 12 pa-
tients in NPC Group 2 yielded sufficient numbers of 
cells  for  phenotypic  and  functional  analysis.  For 
phenotype  analyses  the  EBV-specific  CTLs  set  up 
from  NPC  Group  1  patients  showed  a  higher  per-
centage of CD3+CD8+ T cells (23.6-77.4%) compared to 
NPC Group 2 patients (26.7-75.8%), while there are 
more  percentage  of  CD3-CD16+  NK  cells  in 
EBV-specific CTLs set up from NPC Group 2 patients 
(8.4-60.6%)  compared  to  NPC  Group  1  patients 
(0.6-40.3%) as shown in Table 3. In addition, we also 
examined the frequency of LMP1 and LMP2 HLA-A2 
binding  epitopic  antigen  specific  CTLs  in  auto-LCL 
stimulated EBV-specific CTLs from two NPC group 
patients. The frequency of LMP1 and LMP2 epitopic 
antigen-specific  T  cells  is  usually  higher  in  NPC 
Group  1  EBV-CTL  cultures  than  in  NPC  Group  2 
EBV-CTL cultures similar as that of in PBMCs, fur-
thermore  the  frequency  of  FLY,  GLG  and  CLG 
(LMP2)  epitopic  antigen-specific  CTLs  in  EBV-CTL 
cultures  was  significantly  higher  in  NPC  Group  1 
compared with NPC Group 2 (P <0.05, Fig. 2B). 
Three patterns of cytotoxic responses could be 
discerned  in  the  polyclonal  EBV-specific  CTL  cul-
tures. The majority of auto-LCL stimulated cultures 
from NPC Group 1 patients, 8 out of 10, showed a 
Pattern I corresponding to EBV-specific MHC class I 
restricted cytotoxicity and 2 patients showed a Pattern 
II  lysis  corresponding  to  a  mixture  of  EBV-specific 
and  non-specific,  NK-like  cytotoxicity  (Table  3).  In 
contrast, only 1 of 4 patients in NPC Group 2 showed 
at Pattern I response, 2 showed Pattern II and in 1 case 
of NPC Group 2 the proliferating cells were not cyto-
toxic (Pattern III). This failure to reactivate strong EBV 
specific  effectors was  confirmed when the response 
was  evaluated  by  the  capacity  to  release  IFN  fol-
lowing  stimulation  with  PMA/inomycin  or  autolo-
gous  LCLs,  the  percentage  of  CD3+ IFN-producing 
cells  was  significantly  higher  in  EBV-CTL  cultures 
from NPC Group 1 compared to NPC Group 2 after 
stimulation  by  PMA/inomycin  or  autologous  LCL 
(P<0.05, Fig. 4A and B).  
 
 
 
Table 3.  Phenotype and cytotoxic activity of auto-LCL stimulated CTL cultures from PBMC of NPC Group 1 and NPC 
Group 2 patients. 
Group  Sample  CD8+CD3+/ CD3-CD16+ in PBMCs (%)  CD8+CD3+/CD3-CD16+ in CTLs (%)  Cytotoxic lysis Patterna 
NPC Group 1  P13  29.3/18.8  84.3/4.2  I 
P19  18.5/-b  57.6/10.1  I 
P32  17.4/30.7  51.8/22.3  I 
P34  26.7/21.6  61.8/14.6  I 
P35  21.2/34.7  58.3/6.7  I 
P47  17.3/25  63.1/14.3  I 
P50  22.8/21.4  88/5.1  I 
P51  28/22.9  49.5/48.3  II 
P52  33.5/36.8  58.4/10.1  II 
P54  17.6/18  55.1/1.6  I 
NPC Group 2  P28  10.2/43.5  54.7/22.5  II 
P49  18.9/36.6  30.2/60.6  III 
P56  16.8/29.7  26.7/29.7  II 
P57  15.5/13.2  66/5.6  I 
a. Score system: Pattern I=Specific lysis; Pattern II=non-specific lysis; Pattern III= no lysis. b. not done 
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Figure 4. Intracellular staining for INF- releasing of EBV-CTL lines from NPC Group 1 and NPC Group 2 after 
stimulated with Phorbol ester (PMA)/Inomycin, auto-LCL and auto-PHA blast. P35 and P56 CTL lines were the 
representative of the patients from NPC Group 1 and NPC Group 2 (A); compared the percentage of IFN- positive cells 
of EBV-CTL lines from NPC Group 1 (n=8) and NPC Group 2 patients (n=5) with or without stimulation. (B) * means 
P<0.05 
 
Phenotypic characterization of tumor biopsies in 
two NPC groups 
We  finally  asked  whether  the  different  im-
munophenotype detected in the peripheral blood of 
the patients of two NPC groups might correlate with 
the characteristics of the tumors. To this end the ex-
pression of HLA class I and class II, CD54, chemo-
kines and chemokine receptors including IP-10, SDF-1 
and CXCR-4, and the EBV LMP1 antigen were inves-
tigated  by  immunohistochemical  staining  in  tumor 
specimen derived from two groups of patients (Table 
4). Nineteen of the 36 NPC specimen included in this 
study (52.7%) were LMP1 positive. Interestingly, 15 
out of 19 (78.9%) were derived from NPC Group 1 
patients, while only 4 of 19 (21.1%) were from NPC 
Group 2 patients (P<0.05). Biopsies from NPC Group 
2 patients also showed a significantly decreased ex-
pression of HLA-DR protein (3/14, 22% compared to 
15/22,  68%,  P<0.05)  while  there  was  no  statistical 
difference  in  the  expression  of  HLA  class  I 
(-microglobulin),  CD54,  IP-10,  SDF-1  and  CXCR4 
on tumor cells between two NPC groups samples. Int. J. Biol. Sci. 2011, 7 
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Table 4. The characteristics of NPC tumor tissues in NPC Group 1 and NPC Group 2 patients 
Tumor Marker  NPC Group 1 (%)  NPC Group 2 (%)  P valueb 
Low  High  Low  High 
HLA-antigensa           
β2-Microglobulin  11 (50)  11 (50)  10 (72)  4 (28)  0.2 
HLA-DR  7 (32)  15(68)  11 (78)  3 (22)  0.0062* 
CD54  7 (32)  15 (68)  4 (28)  10 (72)  0.83 
Chemokines and receptors           
IP-10  7 (32)  15 (68)  2(14)  12(86)  0.23 
SDF-1  14 (63)  8 (37)  7 (50)  7 (50)  0.41 
CXCR4  15 (68)  7 (32)  10 (72)  4 (28)  0.83 
EBV antigensc           
LMP1  7(31)  15(69)  10(75)  4(25)  0.02* 
a. Low= - to +; high= ++ to +++ 
b. * means significant difference 
c.  LMP1 Low= -; high= + 
 
 
DISCUSSION 
Most non-keratinizing NPC and undifferentiated 
NPC are associated with EBV infection and  several 
EBV latent type II antigens,  such as EBNA1, LMP1 
(40-60%) and LMP2 are expressed on the tumor cells 
[11, 27]. Therefore, NPC is a good candidate for im-
munotherapy based on adoptive transfer of EBV spe-
cific CTLs [28]. However, the clinical application of 
this therapeutic strategy in NPC still need to improve 
therapy efficacy [16, 17, 29]. Since the long term re-
sults of this type of therapeutic intervention may be 
critically influenced by the immune status of the pa-
tients, we sought to identify immune parameters that 
could  allow  the  stratification  of  NPC  patients  into 
subgroups with different competence to mount effi-
cient EBV-specific responses. Using as distinguishing 
parameter  the  presence  of  significantly  reduces  cir-
culating CD3+ T-lymphocytes at the time of diagnosis 
we  could  identify  two  subgroups  of  NPC  patients. 
Two-third of the patients, belonging to NPC Group 1, 
have normal levels of CD3+ T cells (>52.6%), and show 
a  decrease  of  both  CD3+CD45RA+  and  CD4+CD25- 
naïve T cells population and increase of CD4+CD25+ 
Treg cells population. The remaining one third of the 
patients,  belonging  to  NPC  Group  2,  exhibited  a 
phenotype  of  more  severe  immune  suppression,  as 
the  percentage  of  CD3+CD45RO+  memory  cells  and 
CD3+  T-cells  including  CD3+CD8+  T-cells  and 
CD3+CD4+  T  cells  were  significantly  decreased.  In 
addition, the NPC Group 2 also showed a decrease of 
naïve T cells and increase of Treg cells, and the lower 
frequency  of  LMP1  and  LMP2  epitopic  anti-
gen-specific T cells in PBMCs. Furthermore the serum 
level of IFN is lower in NPC Group 2 patients com-
pared to NPC Group 1 patients. This correlated with a 
stronger  imbalance  in  the  control  of  EBV  infection 
since the patients falling in this group had also higher 
virus load in the blood and higher serum titers of an-
tibodies specific for viral antigens expressed during 
the  productive  virus  cycle  [Fig  3].  In  accordance,  a 
significantly higher proportion of these patients failed 
to mount efficient EBV-specific T cell responses upon 
stimulation  of  PBMC  with  autologous  EBV  trans-
formed LCLs. The phenotype of EBV-CTL cultures set 
up from NPC Group 2 showed a higher percentage of 
CD3-CD16+  NK  cells  and  less  percentage  of 
CD3+CD8+ T cells, and a less frequency of LMP1 and 
LMP2 epitopic antigen-specific CTLs (Table 3 and Fig. 
2B), besides that this conclusion is also supported by 
the capacity of CTL cultures reactivated in vitro to kill 
autologous virus infected cells in  51Cr release assays 
and also by the production of TH1 cytokines such as 
IFN- [Table 3 and Fig 4].  
We  did  not  observe  any  consistent  correlation 
between the immune status revealed by the pheno-
type of circulating lymphocytes and the age and sex 
distribution  or  clinical  parameters  of  the  patients. 
However, it has been reported that the expression of 
neo-antigens,  the  antigen  transferred  proteins  in-
cluding  HLA-class  I  and  class  II  proteins  or  the 
chemokines and chemokine receptors on tumor cells 
would affect the immune response of tumor micro-
environment and peripheral immune system of host 
[30-34]. To illustrate the correlation of tumor markers 
and immunophenotype of NPC patients, here we in-
vestigated the expression of EBV LMP1 antigen and 
immune related proteins including HLA class I pro-
tein β2-Microglobulin, HLA-DR, CD54, IP-10, SDF-1 
and  CXCR4  in  NPC  tumor  tissues  by  immuno-Int. J. Biol. Sci. 2011, 7 
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hisochemical staining. Our results suggested that the 
majority of the patients in NPC Group 1 carried LMP1 
positive tumors (69%) while only 25% of patients in 
NPC Group 2 carried LMP1 positive tumors (P<0.05). 
In accordance with their LMP1 expression on the tu-
mor cells, the NPC Group 1 patients also expressed 
higher  levels  of  HLA-DR  protein  on  tumor  cells 
compared  with  NPC  Group  2  patients  (68%  versus 
22%, P<0.01) (Table 4). Interestingly, we thought that 
the  lower  LMP1  and  HLA-DR  expression  level  on 
tumor cells should be associated with immune dys-
function in NPC Group 2 patients including the de-
crease  of  CD3+,  CD3+CD8+  and  CD3+CD4+  subsets 
and the decrease of the frequency of LMP1 epitopic 
antigen-specific T cells, and the weak capacity to set 
up EBV-CTL cultures and EBV-specific immune re-
sponse in vitro. It has been identified that generation 
the EBV-antigen specific CTLs such as LMP2 which 
expressed on NPC tumor cells, or producing a selec-
tively  lymphodepletion  for  patients  by  using 
CD45mAb  before  EBV-CTL  infusion  could  improve 
the clinical benefit of T cell immunotherapy for NPC 
[15, 35], so that the antigens presented on tumor cells 
and the immune status of patients maybe decide the 
response to EBV-CTL immunotherapy.   
In this study, most patients (58/67) are in late 
disease stage  (Stage  III  and  IV)  due  to  the  difficult 
diagnosis for NPC at early stage. All these patients 
accepted  the  conventional  therapy  including  radio-
therapy and chemotherapy. Until the last follow-up 
time in the beginning of 2011, we could not observe 
any  correlation  between  immunological  difference 
and the clinic outcome in our groups’ patients during 
5 year follow-up; this might be due to the limitation of 
the patient number. However, in our recently research 
we found that the density of some tumor infiltrating 
lymphocyte subsets such as Foxp3+ TILs, CD8+ TILs 
and CD8+GrB+ TILs were correlated with the clinico-
pathology or prognosis of NPC patients [36]. These 
findings maybe demonstrate that tumor immune mi-
croenvironment more directly contribute to the pro-
gress  and  prognosis  of  cancer  than  the  peripheral 
immune system. 
In summary, we showed for the first time that 
NPC patients can be stratified in two subgroups based 
on the immunophenotype of their PBMCs at the time 
of  diagnosis.  Poor  immunophenotypic  NPC  group 
shows a significant correlation with a diminished ca-
pacity to control EBV infection and with the carriage 
of LMP1 negative tumors and decrease of HLA-DR 
antigen  expression  on  tumor  cells.  These  findings 
maybe  provide  some  information  in  guiding  the 
choice  of  patients  that  may  benefit  from  immuno-
therapy based on adoptive transfer of EBV-CTL.  
SUPPLEMENTARY MATERIAL 
Table S1. The number and phenotype of PBMCs from 
the patients of NPC Group 1 and Group 2.   
Figure S1. Representative dot plots for CD8 and te-
tramer staining in PBMCs (A) and EBV-CTL cultures 
(B) from one NPC patient of NPC Group 1.   
http://www.biolsci.org/v07p0607s1.pdf 
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